

Comparative evaluation of immune response after laparoscopic and open total mesorectal excisions with anal sphincter preservation in patients with rectal cancer

Jian-Kun Hu, Zong-Guang Zhou, Zhi-Xin Chen, Lan-Lan Wang, Yong-Yang Yu, Jin Liu, Bo Zhang, Li Li, Ye Shu, Jia-Ping Chen

Jian-Kun Hu, Zong-Guang Zhou, Zhi-Xin Chen, Yong-Yang Yu, Bo Zhang, Li Li, Ye Shu, Jia-Ping Chen, Department of General Surgery and Institute of Digestive Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Lan-Lan Wang, Jin Liu, Laboratory of Clinical Immunology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China

Supported by the Key Project of National Outstanding Youth Foundation of China, No. 39925032

Correspondence to: Zong-Guang Zhou, Department of General Surgery and Institute of Digestive Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China. zhou767@21cn.com

Telephone: +86-28-85422479 **Fax:** +86-28-85422484

Received: 2003-05-12 **Accepted:** 2003-06-02

Abstract

AIM: The study of immune response of open *versus* laparoscopic total mesorectal excision with anal sphincter preservation in patients with rectal cancer has not been reported yet. The dissected retroperitoneal area that contacts directly with carbon dioxide is extensive in laparoscopic total mesorectal excision with anal sphincter preservation surgery. It is important to clarify whether the immune response of laparoscopic total mesorectal excision with anal sphincter preservation (LTME with ASP) in patients with rectal cancer is suppressed more severely than that of open surgery (OTME with ASP). This study was designed to compare the immune functions after laparoscopic and open total mesorectal excision with anal sphincter preservation for rectal cancer.

METHODS: This study involved 45 patients undergoing laparoscopic ($n=20$) and open ($n=25$) total mesorectal excisions with anal sphincter preservation for rectal cancer. Serum interleukin-2 (IL-2), interleukin-6 (IL-6), tumor necrosis factor α (TNF $_{\alpha}$) were assayed preoperatively and on days 1 and 5 postoperatively. CD3 $^{+}$ and CD56 $^{+}$ T lymphocyte count, CD3 $^{-}$ and CD56 $^{+}$ natural killer cell (NK) count and immunoglobulin (IgG/IgM/IgA) were assayed preoperatively and on day 5 postoperatively. The numbers of CD3 $^{+}$ and CD56 $^{+}$ T lymphocytes and CD3 $^{-}$ and CD56 $^{+}$ NK cells were counted using flow cytometry. An enzyme-linked immunosorbent assay (ELISA) was used for IL-2, IL-6 and TNF $_{\alpha}$ determination. And IgG, IgM, and IgA were assayed using immunonephelometry.

RESULTS: The demographic data of the two groups had no difference. The preoperative levels of CD3 $^{+}$ and CD56 $^{+}$ T lymphocyte count, CD3 $^{-}$ and CD56 $^{+}$ NK count, serum IgG, IgM, IgA, IL-2, IL-6 and TNF $_{\alpha}$ also had no significant difference in the two groups ($P>0.05$). The CD3 $^{+}$ and CD56 $^{+}$ T lymphocyte counts had no obvious changes after surgery in laparoscopic ($d=-0.79\pm 3.83\%$) and open ($d=0.42\pm 2.09\%$) groups. The CD3 $^{-}$ and CD56 $^{+}$ NK counts were decreased

postoperatively in both laparoscopic ($d=-7.23\pm 11.33\%$) and open ($d=-9.21\pm 13.93\%$) groups. The differences of the determined values of serum IgG, IgM and IgA on the fifth day after operation subtracted those before operation were -2.56 ± 2.14 g/L, -252.35 ± 392.94 mg/L, -506.15 ± 912.24 mg/L in laparoscopic group, and -1.81 ± 2.10 g/L, -282.72 ± 356.75 mg/L, -252.20 ± 396.28 mg/L in open group, respectively. The levels of IL-2 were decreased after operation in both groups. However, the levels of IL-6 were decreased after laparoscopic surgery ($d_1=-23.14\pm 263.97$ ng/L and $d_5=-40.08\pm 272.03$ ng/L), and increased after open surgery ($d_1=27.38\pm 129.14$ ng/L and $d_5=21.67\pm 234.31$ ng/L). The TNF $_{\alpha}$ levels were not elevated after surgery in both groups. There were no significant differences in the numbers of CD3 $^{+}$ and CD56 $^{+}$ T lymphocytes and CD3 $^{-}$ and CD56 $^{+}$ NK cells, the levels of IgG, IgM, IgA, IL-2, IL-6 and TNF $_{\alpha}$ between the two groups ($P>0.05$).

CONCLUSION: There are no differences in immune responses between the patients having laparoscopic total mesorectal excision with anal sphincter preservation and those undergone open surgery for rectal cancer.

Hu JK, Zhou ZG, Chen ZX, Wang LL, Yu YY, Liu J, Zhang B, Li L, Shu Y, Chen JP. Comparative evaluation of immune response after laparoscopic and open total mesorectal excisions with anal sphincter preservation in patients with rectal cancer. *World J Gastroenterol* 2003; 9(12): 2690-2694

<http://www.wjgnet.com/1007-9327/9/2690.asp>

INTRODUCTION

General anesthesia, major surgery, and severe trauma are all known to cause significant inhibition of the immune response^[1]. The immunosuppression associated with major surgery is believed to contribute to the increased risk of metastasis and sepsis in the postoperative period^[1]. In order to improve the immune response of postoperative patients, minimally invasive surgery has been performed. Reduced hospital stay, less wound pain, earlier resumption of diet and recovery of bowel function are recognized as benefits of laparoscopic cholecystectomy or colectomy^[2]. The effects of laparoscopic colorectal surgery on the immune system varied from study to study. Meanwhile, study on immune response of open *versus* laparoscopic total mesorectal excision with anal sphincter preservation in patients with rectal cancer has not been reported yet. The dissected retroperitoneal area that contacts directly with carbon dioxide is extensive in laparoscopic total mesorectal excision with anal sphincter preservation surgery. It is important to clarify whether the immune response of laparoscopic total mesorectal excision with anal sphincter preservation (LTME with ASP) in patients with rectal cancer is suppressed more severely than that of open surgery (OTME with ASP). The aim of this nonrandomized prospective study was to compare the effects of LTME and OTME on immune response.

MATERIALS AND METHODS

Patients selection

From October 2001 to July 2002, 49 patients admitted to the General Surgery Department of West China Hospital with the diagnosis of rectal cancer confirmed by pathology were prospectively evaluated. The criterion for inclusion in the study was patients diagnosed with biopsy as adenocarcinoma of the rectum localized below 15 cm from the anal margin. The criteria for exclusion included age older than 80 years and younger than 18 years, presence of a fixed palpable mass or cancer infiltrating adjacent organs, evidence of metastatic disease, neoadjuvant chemoradiotherapy, severe cardiovascular (New York Heart Association class 3 or more) or respiratory dysfunction, patients with previous abdominal operation, acute intestinal obstruction or perforation, any malignancy within the recent 5 years, synchronous multiple adenocarcinomas and pregnancy, any contraindication to pneumoperitoneum, and patients with unresectable tumor.

Preoperative examinations including flexible endoscopy as well as biopsy, ultrasonography, computed tomography scan, radiography of the chest, etc. were routinely performed. All patients underwent preoperative bowel preparation (1L 10% mannite electrolyte solution). Prophylactic antibiotics of ciprofloxacin and metronidazole were routinely given orally for three days before operation. A urinary catheter and a nasogastric tube were routinely used.

Data collection

The parameters measured were demographic data, operating time, distance of the tumor from the anal margin, time of first passing flatus, time removing urinary catheter, duration of hospital stay, postoperative complications and death. Demographic data included age, sex, serum total protein (TP), albumin (Alb), hemoglobin (Hb), weight, and underlying diseases.

Operation techniques

All patients were administered general anesthesia and operations were carried out in lithotomy position with 15° head-down tilt. Premedication and anesthetic techniques were standardized. Induction was made by intravenous injection of 3-5 mg/kg thiopentone together with fentanyl. Anesthesia was maintained by ventilation with an O₂/N₂O mixture and isoflurane. Operations were performed by surgeons experienced in both laparoscopic and conventional surgeries. The rectal surgery was performed according to the principle of total mesorectal excision (TME)^[3,4]. Our laparoscopic techniques were reported previously^[5].

Pneumoperitoneum was introduced through subumbilical incision to maintain the pressure at 12-14 mmHg (1 mmHg=0.133 kPa). Camera port with subumbilical trocar was first created, then one operative port in the right midclavicular line at the level of umbilicus, and other two operative ports in the left and right McBurney point were also created respectively under the guidance of laparoscopic view to facilitate dissection. A laparoscope with 25 or 30 curvy degree was inserted into the abdominal cavity via a subumbilical trocar, following the no-touch technique. Routine exploration was performed to ascertain whether the tumor metastasized to the organs in the abdominal cavity and infiltrated the serosa or implanted in the abdominal cavity. With the operation proceeding of total mesorectal excision, division was moved downward into the pelvis along the anatomic space between visceral and parietal endopelvic fascia. In order to extract the bowel loop of the tumor, the port at the left McBurney's point was extended to about 3.5 cm long, the tumor was routinely isolated by inserting it into a sheath-shaped bacteria-free plastic bag through the

incision, and the tumor as well as the proximal colon were extracted through the bag, and then the bowel was transected at the level of 10-15 cm above upper margin of the tumor. After the anvil of a 29 mm-sized circular stapler was inserted into the end of the proximal bowel and secured with 2/0 prolene purse-string suture, the proximal bowel was internalized and the extended incision was closed. Pneumoperitoneum was then induced again, and laparoscopic colo-anal or colo-rectal anastomosis was performed using a CDH 29 circular stapler.

Immunological studies

Seven milliliters of venous blood were taken by peripheral venipuncture before surgery and on days 1 and 5 after surgery into one plain vacutainer and one heparin vacutainer. The specimens were centrifuged and the collected serum was stored at -20 °C for the assay of interleukin-2 (IL-2), interleukin-6 (IL-6) and tumor necrosis factor α (TNF α). IL-2, IL-6 and TNF α were assayed preoperatively and on days 1 and 5 postoperatively. CD3⁺ and CD56⁺ T lymphocyte count, CD3⁻ and CD56⁺ natural killer cell (NK) count and immunoglobulin (IgG/IgM/IgA) were determined preoperatively and on day 5 postoperatively. The numbers of CD3⁺ and CD56⁺ T lymphocytes and CD3⁻ and CD56⁺ NK cells were counted using flow cytometry (Elite-Esp, Beckman-Coulter, USA). An enzyme-linked immunosorbent assay (ELISA) was used for IL-2, IL-6 and TNF α determination (Bio-Rad system, Immune Company, France), and immunoglobulin (Ig) G, IgM, and IgA were assayed using immunonephelometry (Immage analyzer, Beckman-Coulter, USA).

Statistics analysis

All the data were collected on designed forms, and analyzed with SPSS version 10.0 software. The differences of the determined values on fifth or first postoperative day subtracted those before operation were compared between laparoscopic and open groups. Student's *t* test was used for quantitative variables and chi-square test for qualitative variables. All *P* values were two sided. Statistical significance was established as *P*<0.05. The data were expressed as mean \pm standard deviation (SD).

RESULTS

A total of 49 patients were entered into the study. Four patients did not meet the eligibility criteria for the trial (three in laparoscopic group and one in open). Three were found to have hepatic metastasis and one did not receive resection because the cancer infiltrated several adjacent organs.

Patient characteristics

The demographic features of the patients are shown in Table 1. The two groups had no differences with respect to age, gender, TP, Alb, Hb, weight and Duke's classification (*P*>0.05).

Surgical treatment

Table 2 shows the results of the two treatments. All the 45 patients received the curative anterior resection with total mesorectal excision, and the low/ultralow/colo-anal anastomosis was performed by laparoscopic or open surgery. In laparoscopic group, no one required conversion to open surgery.

There was no surgical death in both groups. Operation time was significantly longer in the laparoscopic group than that in the open group (226.75 \pm 46.15 min *versus* 146.40 \pm 38.09 min, *P*<0.05). The time of first passing flatus in laparoscopic group was significantly shorter than that in the open group (3.15 \pm 1.14 min *versus* 4.36 \pm 1.19 min, *P*<0.05). There were

no differences in time of removing urinary catheter, duration of hospital stay and distance of tumor from anal margin between the two groups ($P>0.05$).

The two groups of patients had comparable preoperative underlying diseases. As for the postoperative complications, one patient in the open group had anastomotic leakage and one in the same group experienced wound infection, both of them were successfully treated conservatively. There was no postoperative complication in the laparoscopic group. There were no local recurrence, port site recurrence, and mortality in any patients observed during follow-up ranged from 8 to 17 months.

Table 1 Demographic and clinical characteristics of patients (mean \pm SD)

	LTME $n=20$	OTME $n=25$	P value
Age (year)	61.60 \pm 8.44	57.96 \pm 10.70	0.213
Sex (n)			>0.05
M	9	16	
F	11	9	
TP (g/L)	69.36 \pm 5.14	71.55 \pm 8.23	0.298
Alb (g/L)	41.70 \pm 4.16	43.36 \pm 4.49	0.199
Hb (g/L)	123.05 \pm 14.43	125.18 \pm 15.14	0.627
Weight (kg)	58.45 \pm 7.86	59.88 \pm 10.85	0.619
Duke's classification (n)			>0.05
A	10	6	
B	4	7	
C ₁	3	7	
C ₂	3	5	
Underlying diseases (n)			>0.05
Diabetes mellitus	1	0	
Hypertension	1	1	
Anemia	0	2	

Table 2 Surgical treatment of patients

	LTME $n=20$	OTME $n=25$	P value
Operating time (min)	226.75 \pm 46.15	146.40 \pm 38.09	0.000 ^b
Time of first passing flatus (day)	3.15 \pm 1.14	4.36 \pm 1.19	0.001 ^b
Time of removing urinary catheter (day)	7.35 \pm 2.18	6.28 \pm 1.59	0.065
Duration of hospital stay (day)	18.30 \pm 4.28	18.04 \pm 5.47	0.863
Distance of tumor from anal margin (cm)	8.35 \pm 3.72	7.00 \pm 3.93	0.247

^b $P<0.01$ vs open group.

Immune response

As expected, the preoperative levels of CD3⁺ and CD56⁺ T lymphocyte count, CD3⁻ and CD56⁺ NK count, serum IgG, IgM, IgA, IL-2, IL-6 and TNF α had no difference in the two groups (Table 3, $P>0.05$).

Table 3 Preoperative immune indicators of two groups (mean \pm SD)

	LTME $n=20$	OTME $n=25$	P value
CD3 ⁺ CD56 ⁺ T (%)	4.56 \pm 5.08	3.74 \pm 4.19	0.556
CD3 ⁻ CD56 ⁺ NK (%)	20.87 \pm 13.76	25.41 \pm 16.79	0.335
IgG (g/L)	11.50 \pm 2.41	12.61 \pm 2.90	0.178
IgM (mg/L)	1 407.40 \pm 420.27	1 582.40 \pm 735.41	0.350
IgA (mg/L)	2 726.40 \pm 2 048.28	2 380.16 \pm 928.99	0.454
IL-2 (ng/L)	85.20 \pm 303.81	128.30 \pm 387.12	0.686
IL-6 (ng/L)	88.70 \pm 231.52	49.06 \pm 81.63	0.429
TNF α (ng/L)	7.69 \pm 5.71	12.99 \pm 26.61	0.387

Table 4 shows the differences of the values of IL-2, IL-6 and TNF α on the fifth or first postoperative day subtracted those before operation, respectively. The TNF α levels were not elevated after surgery, and there were no significant differences between the two groups ($P>0.05$). However, the levels of IL-6 were decreased after laparoscopic surgery ($d_1=-23.14\pm 263.97$ ng/L and $d_5=-40.08\pm 272.03$ ng/L), but there were no significant differences between the laparoscopic and open groups ($P>0.05$). The levels of IL-2 were decreased after operation in both groups, the differences were no significant in postoperative days between the two groups ($P>0.05$).

Table 4 Changes of IL-2, IL-6 and TNF α after surgery in two groups (mean \pm SD)

		LTME $n=20$	OTME $n=25$	P value
IL-2(ng/L)	d_1	-80.54 \pm 304.30	-98.82 \pm 412.38	0.869
	d_5	-27.55 \pm 344.29	-33.59 \pm 560.20	0.967
IL-6(ng/L)	d_1	-23.14 \pm 263.97	27.38 \pm 129.14	0.405
	d_5	-40.08 \pm 272.03	21.67 \pm 234.31	0.418
TNF α (ng/L)	d_1	2.23 \pm 12.78	-1.01 \pm 7.82	0.301
	d_5	1.84 \pm 12.84	0.56 \pm 9.86	0.705

(d_1 =the differences of the values of IL-2, IL-6 and TNF α on the first postoperative day subtracted those before operation, respectively. d_5 = the differences of the values of IL-2, IL-6 and TNF α on the fifth postoperative day subtracted those before operation, respectively).

Table 5 shows the differences of the values of CD3⁺ and CD56⁺ T lymphocyte count, CD3⁻ and CD56⁺ NK count, and serum IgG, IgM, and IgA on the fifth postoperative day from those before operation, respectively. There were no significant differences of CD3⁺ and CD56⁺ T lymphocyte count, CD3⁻ and CD56⁺ NK count, and serum IgG, IgM, and IgA levels after surgery between the two groups ($P>0.05$).

Table 5 Changes of CD3⁺ CD56⁺ T lymphocyte count, CD3⁻ CD56⁺ NK count, and serum immunoglobulin after surgery in two groups (mean \pm SD)

	LTME $n=20$	OTME $n=25$	P value
CD3 ⁺ CD56 ⁺ T lymphocyte (%)	-0.79 \pm 3.83	0.42 \pm 2.09	0.214
CD3 ⁻ CD56 ⁺ NK (%)	-7.23 \pm 11.33	-9.21 \pm 13.93	0.609
IgG (g/L)	-2.56 \pm 2.14	-1.81 \pm 2.10	0.248
IgM (mg/L)	-252.35 \pm 392.94	-282.72 \pm 356.75	0.787
IgA (mg/L)	-506.15 \pm 912.24	-252.20 \pm 396.28	0.216

Numbers listed were the differences of the values of CD3⁺ CD56⁺ T lymphocyte count, CD3⁻ CD56⁺ NK count, and serum IgG, IgM, IgA on the fifth postoperative day subtracted those before operation, respectively.

DISCUSSION

Rectal cancer is the common malignance in our country. Studies on rectal cancer have made great progresses both in clinical practice^[6-15] and in theoretical basis^[16-26] during the latest years. Multiple clinical studies have demonstrated the correlation of high pelvic recurrence with the degree of mesorectal excision^[27]. Residual mesorectum, especially inadequate excision of distal mesorectum (DMR), contributed to poor oncologic outcomes. In order to reduce the rate of local recurrence in the pelvis of rectal carcinoma, total mesorectal excision (TME) has been performed in many colorectal surgery centers. TME has been applied in clinical practice, and the local recurrence rate has decreased dramatically to 5-7.1%^[28,29],

while the mean local recurrence rate of conventional operative procedure for treatment of rectal cancer remained 18.5%. TME has been claimed to improve not only local recurrence rate, but also long term survival^[30-34]. With the improvement of laparoscopic technique, laparoscopic colorectal surgery has been attempted in many countries^[4,35-39]. The laparoscopic colorectal surgery has been proposed to be less traumatic than open surgery. It has been demonstrated that laparoscopic-assisted colectomy has many advantages during immediate postoperative period over the open colectomy with regard to the disappearance of postoperative ileus, fewer analgesia, early ambulation, less postoperative complications, and shorter hospital stay^[4,35-39]. In this study, the time of first flatus in the laparoscopic group was significantly shorter than that in the open group.

Some randomised clinical trials of open versus laparoscopically assisted colectomy on systematic immunity in patients with colorectal cancer have been performed. Delgado *et al*^[40] found that the plasma levels of cortisol and prolactin were higher in postoperative period, but no significant differences were observed between both groups of the patients. The level of interleukin-6 was higher with significant differences at 4, 12 and 24 hours in the patients undergone open colectomy than that in laparoscopic group. The plasma level of C-reactive protein (CRP) was significantly lower at 72 hours in patients receiving laparoscopic-assisted colectomy than that in patients receiving open one. They suggested that acute phase systematic response was attenuated in patients undergone laparoscopic-assisted colectomy in comparison with those undergone open colectomy. Leung *et al*^[41] clarified tissue trauma as reflected by systematic cytokine response, such as interleukin-1 β , interleukin-6 and CRP, was less after laparoscopic resection than after open resection of rectosigmoid carcinoma. Nishiguchi *et al*^[42] showed that interleukin-6 and CRP levels were significantly higher in the open group than those in the laparoscopic group one day and two days after surgery, respectively. Lymphocyte counts were significantly higher in the laparoscopic group than those in the open group two days after surgery. They concluded that laparoscopic surgery for colorectal carcinoma led to less postoperative stress than conventional open surgery. Some researchers verified that the levels of serum IL-2, CRP, and TNF α were significantly lower after surgery in the laparoscopic group than those in the open group^[43-45]. Braga *et al*^[46] also found that laparoscopic colorectal surgery was associated with less pronounced immunosuppression and inflammatory response and lower consumption of analgesic drugs than open surgery. But Tang *et al*^[47] and Mehigan *et al*^[48] showed that there was no difference in the systematic immune response in patients having laparoscopically assisted colectomy compared with those undergone conventional open surgery for colorectal cancer. Sandoval *et al*^[49] also revealed that the laparoscopic surgery did not affect natural antitumoral cellular immunity in an animal model. Moreover, Fukushima *et al*^[50] found that serum IL-6 after surgery was significantly higher in laparoscopic sigmoid colectomy than in the open group. They proposed that early IL-6 response after surgery be associated with operation time.

Previous immune response studies were only performed in colorectal surgery. However, the study on immune response of open *versus* laparoscopic total mesorectal excision with anal sphincter preservation in patients with rectal cancer has not been reported yet. The dissected retroperitoneal area that contacted directly with carbon dioxide was extensive in laparoscopic total mesorectal excision with anal sphincter preservation surgery. It is important to clarify whether the immune response of laparoscopic total mesorectal excision with anal sphincter preservation in patients with rectal cancer is

suppressed more severely than that of open surgery or not. In this study, TNF α levels were not elevated after surgery, and there were no significant differences between the two groups ($P>0.05$). However, the levels of IL-6 were decreased after laparoscopic surgery ($d_1=-23.14\pm 263.97$ ng/L and $d_5=-40.08\pm 272.03$ ng/L), but there were no significant differences between the laparoscopic and open groups ($P>0.05$). The levels of IL-2 were decreased after operation in both groups, and the differences were not significant in postoperative days between the two groups ($P>0.05$). There were no significant differences in CD3⁺ and CD56⁺ T lymphocyte count, CD3⁻ and CD56⁺ NK count, and serum IgG, IgM, and IgA levels after surgery between the two groups ($P>0.05$). Based on the results of our study, it is concluded that there is difference in immune responses in patients having laparoscopic total mesorectal excision with anal sphincter preservation compared with those undergone open surgery for rectal cancer.

REFERENCES

- 1 Walker CB, Bruce DM, Heys SD, Gough DB, Binnie NR, Eremin O. Minimal modulation of lymphocyte and natural killer cell subsets following minimal access surgery. *Am J Surg* 1999; **177**: 48-54
- 2 Vittimberga FJ Jr, Foley DP, Meyers WC, Callery MP. Laparoscopic surgery and the systemic immune response. *Ann Surg* 1998; **227**: 326-334
- 3 Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery -the clue to pelvic recurrence? *Br J Surg* 1982; **69**: 613-616
- 4 Hartley JE, Mehigan BJ, Qureshi AE, Duthie GS, Lee PW, Monson JR. Total mesorectal excision: assessment of the laparoscopic approach. *Dis Colon Rectum* 2001; **44**: 315-321
- 5 Zhou ZG, Wang Z, Yu YY, Shu Y, Cheng Z, Li L, Lei WZ, Wang TC. Laparoscopic total mesorectal excision of low rectal cancer with preservation of anal sphincter: A report of 82 cases. *World J Gastroenterol* 2003; **9**: 1477-1481
- 6 Sun XN, Yang QC, Hu JB. Pre-operative radiochemotherapy of locally advanced rectal cancer. *World J Gastroenterol* 2003; **9**: 717-720
- 7 Gu J, Ma ZL, Li Y, Li M, Xu GW. Angiography for diagnosis and treatment of colorectal cancer. *World J Gastroenterol* 2003; **9**: 288-290
- 8 Cai SJ, Xu Y, Cai GX, Lian P, Guan ZQ, Mo SJ, Sun MH, Cai Q, Shi DR. Clinical characteristics and diagnosis of patients with hereditary nonpolyposis colorectal cancer. *World J Gastroenterol* 2003; **9**: 284-287
- 9 Liu LX, Zhang WH, Jiang HC. Current treatment for liver metastases from colorectal cancer. *World J Gastroenterol* 2003; **9**: 193-200
- 10 Chen K, Cai J, Liu XY, Ma XY, Yao KY, Zheng S. Nested case-control study on the risk factors of colorectal cancer. *World J Gastroenterol* 2003; **9**: 99-103
- 11 Liu LX, Zhang WH, Jiang HC, Zhu AL, Wu LF, Qi SY, Piao DX. Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer. *World J Gastroenterol* 2002; **8**: 663-667
- 12 Zheng S, Liu XY, Ding KF, Wang LB, Qiu PL, Ding XF, Shen YZ, Shen GF, Sun QR, Li WD, Dong Q, Zhang SZ. Reduction of the incidence and mortality of rectal cancer by polypectomy: a prospective cohort study in Haining County. *World J Gastroenterol* 2002; **8**: 488-492
- 13 Wan J, Zhang ZQ, Zhu C, Wang MW, Zhao DH, Fu YH, Zhang JP, Wang YH, Wu BY. Colonoscopic screening and follow-up for colorectal cancer in the elderly. *World J Gastroenterol* 2002; **8**: 267-269
- 14 Zhang YL, Zhang ZS, Wu BP, Zhou DY. Early diagnosis for colorectal cancer in China. *World J Gastroenterol* 2002; **8**: 21-25
- 15 Qing SH, Rao KY, Jiang HY, Wexner SD. Racial differences in the anatomical distribution of colorectal cancer: a study of differences between American and Chinese patients. *World J Gastroenterol* 2003; **9**: 721-725
- 16 Fang J, Jin HB, Song JD. Construction, expression and tumor tar-

- geting of a single-chain Fv against human colorectal carcinoma. *World J Gastroenterol* 2003; **9**: 726-730
- 17 **Hu HY**, Liu XX, Jiang CY, Zhang Y, Bian JF, Lu Y, Geng Z, Liu SL, Liu CH, Wang XM, Wang W. Cloning and expression of ornithine decarboxylase gene from human colorectal carcinoma. *World J Gastroenterol* 2003; **9**: 714-716
- 18 **Jiang YA**, Fan LF, Jiang CQ, Zhang YY, Luo HS, Tang ZJ, Xia D, Wang M. Expression and significance of PTEN, hypoxia-inducible factor-1 alpha in colorectal adenoma and adenocarcinoma. *World J Gastroenterol* 2003; **9**: 491-494
- 19 **Ma L**, Tai H, Li C, Zhang Y, Wang ZH, Ji WZ. Photodynamic inhibitory effects of three perylenequinones on human colorectal carcinoma cell line and primate embryonic stem cell line. *World J Gastroenterol* 2003; **9**: 485-490
- 20 **Huang ZH**, Fan YF, Xia H, Feng HM, Tang FX. Effects of TNP-470 on proliferation and apoptosis in human colon cancer xenografts in nude mice. *World J Gastroenterol* 2003; **9**: 281-283
- 21 **Chen XX**, Lai MD, Zhang YL, Huang Q. Less cytotoxicity to combination therapy of 5-fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines. *World J Gastroenterol* 2002; **8**: 841-846
- 22 **Xiong B**, Yuan HY, Hu MB, Zhang F, Wei ZZ, Gong LL, Yang GL. Transforming growth factor-beta1 in invasion and metastasis in colorectal cancer. *World J Gastroenterol* 2002; **8**: 674-678
- 23 **Zhou CZ**, Peng ZH, Zhang F, Qiu GQ, He L. Loss of heterozygosity on long arm of chromosome 22 in sporadic colorectal carcinoma. *World J Gastroenterol* 2002; **8**: 668-673
- 24 **Xiong B**, Gong LL, Zhang F, Hu MB, Yuan HY. TGF beta1 expression and angiogenesis in colorectal cancer tissue. *World J Gastroenterol* 2002; **8**: 496-498
- 25 **Li J**, Guo WJ, Yang QY. Effects of ursolic acid and oleanolic acid on human colon carcinoma cell line HCT15. *World J Gastroenterol* 2002; **8**: 493-495
- 26 **Wang X**, Lan M, Wu HP, Shi YQ, Lu J, Ding J, Wu KC, Jin JP, Fan DM. Direct effect of croton oil on intestinal epithelial cells and colonic smooth muscle cells. *World J Gastroenterol* 2002; **8**: 103-107
- 27 **Wexner SD**, Rotholtz NA. Surgeon influenced variables in resectional rectal cancer surgery. *Dis Colon Rectum* 2000; **43**: 1606-1627
- 28 **Killingback M**, Barron P, Dent OF. Local recurrence after curative resection of cancer of the rectum without total mesorectal excision. *Dis Colon Rectum* 2001; **44**: 473-483
- 29 **McCall JL**, Cox MR, Wattchow DA. Analysis of local recurrence rates after surgery alone for rectal cancer. *Int J Colorectal Dis* 1995; **10**: 126-132
- 30 **Law WL**, Chu KW. Impact of total mesorectal excision on the results of surgery of distal rectal cancer. *Br J Surg* 2001; **88**: 1607-1612
- 31 **Dahlberg M**, Pahlman L, Bergstrom R, Glimelius B. Improved survival in patients with rectal cancer: a population-based register study. *Br J Surg* 1998; **85**: 515-520
- 32 **Dahlberg M**, Glimelius B, Pahlman L. Changing strategy for rectal cancer is associated with improved outcome. *Br J Surg* 1999; **86**: 379-384
- 33 **Arenas RB**, Fichera A, Mhoon D, Michelassi F. Total mesenteric excision in the surgical treatment of rectal cancer: a prospective study. *Arch Surg* 1998; **133**: 608-612
- 34 **Heald RJ**, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. *Arch Surg* 1998; **133**: 894-899
- 35 **Chapman AE**, Levitt MD, Hewett P, Woods R, Sheiner H, Maddern GJ. Laparoscopic-assisted resection of colorectal malignancies: a systematic review. *Ann Surg* 2001; **234**: 590-606
- 36 **Feliciotti F**, Paganini AM, Guerrieri M, Sanctis A, Campagnacci R, Lezoche E. Results of laparoscopic vs open resections for colon cancer in patients with a minimum follow-up of 3 years. *Surg Endosc* 2002; **16**: 1158-1161
- 37 **Hong D**, Tabet J, Anvari M. Laparoscopic vs open resection for colorectal adenocarcinoma. *Dis Colon Rectum* 2001; **44**: 10-18
- 38 **Lezoche E**, Feliciotti F, Paganini AM, Guerrieri M, De Sanctis A, Minervini S, Campagnacci R. Laparoscopic vs open hemicolectomy for colon cancer. *Surg Endosc* 2002; **16**: 596-602
- 39 **Maxwell-Armstrong CA**, Robinson MH, Scholefield JH. Laparoscopic colorectal cancer surgery. *Am J Surg* 2000; **179**: 500-507
- 40 **Delgado S**, Lacy AM, Filella X, Castells A, Garcia-Valdecasas JC, Pique JM, Momblan D, Visa J. Acute phase response in laparoscopic and open colectomy in colon cancer: randomized study. *Dis Colon Rectum* 2001; **44**: 638-646
- 41 **Leung KL**, Lai PB, Ho RL, Meng WC, Yiu RY, Lee JF, Lau WY. Systemic cytokine response after laparoscopic-assisted resection of rectosigmoid carcinoma: A prospective randomized trial. *Ann Surg* 2000; **231**: 506-511
- 42 **Nishiguchi K**, Okuda J, Toyoda M, Tanaka K, Tanigawa N. Comparative evaluation of surgical stress of laparoscopic and open surgeries for colorectal carcinoma. *Dis Colon Rectum* 2001; **44**: 223-230
- 43 **Ordemann J**, Jacobi CA, Schwenk W, Stosslein R, Muller JM. Cellular and humoral inflammatory response after laparoscopic and conventional colorectal resections. *Surg Endosc* 2001; **15**: 600-608
- 44 **Schwenk W**, Jacobi C, Mansmann U, Bohm B, Muller JM. Inflammatory response after laparoscopic and conventional colorectal resections-results of a prospective randomized trial. *Langenbecks Arch Surg* 2000; **385**: 2-9
- 45 **Kuntz C**, Wunsch A, Bay F, Windeler J, Glaser F, Herfarth C. Prospective randomized study of stress and immune response after laparoscopic vs conventional colonic resection. *Surg Endosc* 1998; **12**: 963-967
- 46 **Braga M**, Vignali A, Zuliani W, Radaelli G, Gianotti L, Martani C, Toussoun G, Di Carlo V. Metabolic and functional results after laparoscopic colorectal surgery: a randomized, controlled trial. *Dis Colon Rectum* 2002; **45**: 1070-1077
- 47 **Tang CL**, Eu KW, Tai BC, Soh JG, Machin D, Seow-Choen F. Randomized clinical trial of the effect of open versus laparoscopically assisted colectomy on systemic immunity in patients with colorectal cancer. *Br J Surg* 2001; **88**: 801-807
- 48 **Mehigan BJ**, Hartley JE, Drew PJ, Saleh A, Dore PC, Lee PW, Monson JR. Changes in T cell subsets, interleukin-6 and C-reactive protein after laparoscopic and open colorectal resection for malignancy. *Surg Endosc* 2001; **15**: 1289-1293
- 49 **Sandoval BA**, Robinson AV, Sulaiman TT, Shenk RR, Stellato TA. Open versus laparoscopic surgery: a comparison of natural antitumoral cellular immunity in a small animal model. *Am Surg* 1996; **62**: 625-630
- 50 **Fukushima R**, Kawamura YJ, Saito H, Saito Y, Hashiguchi Y, Sawada T, Muto T. Interleukin-6 and stress hormone responses after uncomplicated gasless laparoscopic-assisted and open sigmoid colectomy. *Dis Colon Rectum* 1996; **39**(10 Suppl): S29-S34

Edited by Zhang JZ and Wang XL